Back to results
US 2011/0218185 A1Published application
Azolotriazinone melanin concentrating hormone receptor-1 antagonists
AssigneeBristol-Myers Squibb Company
InventorsPratik Devasthale, William N. Washburn, Kishore V. Renduchintala, Radhakrishnan Sridhar
Life of this patent
Estimating the term…
Abstract
The present application provides compounds that are useful as MCHR1 antagonists, especially for the treatment of obesity, including all stereoisomers, solvates, prodrugs and pharmaceutically acceptable forms thereof according to Formula I wherein the variables are defined herein.
Claims15
A compound of formula I
- or a pharmaceutically acceptable salt or stereoisomer thereof:
- wherein
- is selected from the group consisting of monocyclic aryl or monocyclic heteroaryl;
- W is selected from the group consisting of a direct bond, —O—, and —N(R6)—;
- provided that if W is a direct bond, D is a cyclic amine that is attached to A via the nitrogen atom of the cyclic amine;
- D is selected from the group consisting of a direct bond, substituted or unsubstituted C1 to C4 alkyl, substituted or unsubstituted C3 to C7 cycloalkyl, cycloalkylalkyl, and 4- to 6-membered cyclic amines, provided that if D is a direct bond, R2a, R2b, and R2c are each independently H, alkyl, or cycloalkyl;
- E and G are independently N or CH provided that both are not N;
- R1 is substituted or unsubstituted phenyl or substituted or unsubstituted monocyclic heteroaryl;
- R2a, R2b, and R2c are independently selected from the group consisting of hydrogen, halo, cyano, hydroxyl, —NR5R5a, —SO2R34, —CO2R35—NR5CO2R21, —NR5COR21, substituted or unsubstituted C1 to C4 alkyl, substituted or unsubstituted C3 to C7 cycloalkyl, substituted or unsubstituted 4- to 6-membered cyclic amines wherein said cyclic amine is optionally substituted with —OH, carbonylamino, alkoxycarbonylamino, or at least one of R2a, R2b, and R2c is a prodrug moiety selected from amino acid esters or phosphoric acid esters wherein said amino acid ester has the formula —OC(O)CH(NH2)R31, wherein R31 is H or C1 to C4 alkyl;
- or any two of R2a, Rb, or R2c, may be taken together to form a ring;
- R3 and R3a are each independently selected from the group consisting of hydrogen, hydroxyl, lower alkoxy, halo, CN, substituted or unsubstituted C1 to C4 alkyl, perfluoroalkyl, substituted or unsubstituted C3 to C7 cycloalkyl, and cycloalkoxy, or R3 or R3a and D may optionally be taken together with the atoms to which they are attached to form a 5- to 7-membered ring;
- R5 and R5a are independently selected from the group consisting of hydrogen, substituted or unsubstituted lower alkyl, hydroxyalkyl, hydroxyalkylcycloalkyl, substituted or unsubstituted heterocycloalkyl, acyl, alkoxycarbonyl, carboxyalkyl, substituted or unsubstituted cycloalkyl, and substituted or unsubstituted cycloalkylalkyl, or R5 and R5a and the nitrogen atom to which they are attached may form a ring;
- R21 and R31 are each H or C1 to C4 alkyl;
- R34 is alkyl;
- R35 is H or alkyl;
- and
- R6 is selected from the group consisting of H, C1 to C4 alkyl and C3 to C7 cycloalkyl.
14 more elements
A compound having the following structure or a pharmaceutically acceptable salt thereof, including all stereoisomers thereof:
- wherein
- is phenyl, pyrimidinyl, or pyridinyl;
- R1 is phenyl, pyrimidinyl, or pyridinyl optionally substituted with halo;
- R3a and R3 are independently H or methoxy;
- W is a direct bond or O, provided that if W is a direct bond, D is a cyclic amine that is attached to A via the nitrogen atom of the cyclic amine;
- D is a direct bond, methyl, ethyl, propyl, or a cyclic amine selected from pyrrolidinyl, morpholinyl, azetidinyl, piperidinyl, morpholinyl;
- and
- R2a, R2b, and R2c are independently selected from the group consisting of hydrogen, halo, cyano, hydroxyl, —NR5R5a, —SO2R34, —NR5CO2R21, —NR5COR21, substituted or unsubstituted C1 to C4 alkyl, substituted or unsubstituted C3 to C7 cycloalkyl, substituted or unsubstituted 4- to 6-membered cyclic amines wherein said cyclic amine is optionally substituted with —OH, carbonylamino, alkoxycarbonylamino, or at least one of R2a, R2b, and R2c is a prodrug moiety selected from amino acid esters or phosphoric acid esters wherein said amino acid ester has the formula —OC(O)CH(NH2)R31, wherein R21 and R31 are H or C1 to C4 alkyl;
- or any two of R2a, Rb, or R2c, may be taken together to form a ring;
6 more elements
Dependencies are inferred from the claim text.